Results 171 to 180 of about 55,173 (262)

Clinical and Economic Burden of Obesity and Cardiovascular Disease Among Medicare Fee‐For‐Service Beneficiaries

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This retrospective cohort study described clinical outcomes, healthcare resource utilisation (HCRU), and costs among Medicare beneficiaries with or without obesity and stratified by cardiovascular disease (CVD) risk. Materials and Methods Using Medicare FFS claims (Jan 2016–Dec 2022), beneficiaries were indexed after 12 months of ...
Jiayin Xue   +9 more
wiley   +1 more source

Graph-based understanding of isomeric diversity in complex dissolved organic matter. [PDF]

open access: yesCommun Chem
Liu T   +10 more
europepmc   +1 more source

SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication.
Patrick Muller   +12 more
wiley   +1 more source

Advanced Chlorine Photolysis for Carbamazepine Degradation: Tuning Radicals for Dissolved Organics. [PDF]

open access: yesACS ES T Water
Osei-Appau C   +8 more
europepmc   +1 more source

Importance of Hypercortisolism in BP Control, Cardiovascular Risk and in Patients With Difficult‐to‐Control Hypertension: An Overview for Primary Care Physicians

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Hypertension remains one of the most prevalent and consequential modifiable cardiovascular risk factors worldwide, affecting approximately 1.28 billion adults globally and nearly half of the United States population. Despite the availability of effective therapies, optimal blood pressure control is achieved in fewer than one in four ...
Matthew A. Cavender
wiley   +1 more source

Hypercortisolism: Causes, Consequences and Clinical Significance – A Review of Pathophysiology

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Hypercortisolism or Cushing syndrome is a heterogeneous clinical spectrum caused by chronic glucocorticoid excess, ranging from exogenous Cushing syndrome to rare endogenous aetiologies and the increasingly recognised entity of mild autonomous cortisol secretion (MACS). Physiological cortisol production is tightly regulated by the hypothalamic–
Mohamed Eldib   +3 more
wiley   +1 more source

How Common Is Hypercortisolism in Patients With Hypertension? Risk Factors, Epidemiology, and Making a Diagnosis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Endogenous hypercortisolism (EHC) is an underrecognised and clinically significant contributor to hypertension, particularly resistant hypertension. Once viewed as a rare entity, EHC is now understood as a spectrum of cortisol excess associated with adverse cardiometabolic outcomes and target‐organ damage.
Omar Al Dhaybi, Deepak L. Bhatt
wiley   +1 more source

Home - About - Disclaimer - Privacy